Table 1.
miRNA | Effects | Cancer type | Reference |
---|---|---|---|
Pro-oncogenic | |||
miR-222 | PTEN inhibition- > anti-apoptotic p27/kip inhibition- > cell cycle progression |
breast cancer gastric cancer non-small lung cancer hepatocellular carcinoma |
[104–108] |
miR-485-3p | increased transcription of topoisomerase IIα, multidrug resistance gene 1, cyclin B2- > increased survival, drug resistance, DNA repair | prostate cancer rhabdomyosarcoma lymphoblastic leukemia |
[109, 110] |
miR-100 | interference with HIF1α signalling anti-apoptotic |
breast cancer melanoma |
[39, 111] |
miR-23a | activation of MAPK signalling/inhibition of Sprouty2- > therapy resistance, migration, invasion | breast cancer | [39, 112] |
Anti-oncogenic | |||
miR-145 | growth inhibition- > down-regulation of c-myc and Erk5 | colorectal cancer B-cell lymphomas gastric cancer |
[40, 113–116] |
miR-34a | pro-apoptotic inhibition of cKit/ stemness markers (CD44, BMI-1) |
colorectal cancer prostate cancer |
[117–119] |
let 7 a-c | regulates RAS oncogene | lung cancer breast cancer |
[108, 120–123] |
miR-15/16 | inhibition of bcl2/ CDK1/CDK2 expression | leukemia (CLL) prostate cancer |
[123–125] |